Issue 11, Volume 128

Cover Figure: Genetic risk factors for sclerotic graft-versus-host disease. See the article by Wang et al.

WASHINGTON, September 15, 2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Phosphoproteomic profiling of mouse primary HSPCs reveals new regulators of HSPC mobilization
Wang and colleagues report a robust method of combining multicolor flow cytometry with highly efficient 3-dimensional mass spectrometry for the large-scale phosphoproteomic analysis of rare hematopoietic stem and progenitor cells (HSPCs). They generate a wealth of cellular signaling data related to HSPC mobilization.

Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas
Selective targeting of BCL-2 with venetoclax has shown remarkable efficacy in treating refractory chronic lymphocytic leukemia. Here,The pathogenesis of peripheral T-cell lymphomas is poorly understood, and treatment outcome is highly unsatisfactory. Vallois et al use genome and transcriptome analyses focusing on T-cell receptor (TCR)–related genes. They identify frequent activating mutations in costimulatory/TCR-related signaling genes including potentially druggable targets.

How I treat hepatitis C virus infection in patients with hematologic malignancies
Modern therapy for patients with hematologic disease with hepatitis C is evolving rapidly. This How I Treat article highlights clinical scenarios of hepatitis C virus–infected patients with hematologic malignancies, with a focus on diagnosis, clinical and laboratory presentations, complications, and the choice of newer therapeutic regimens with direct-acting antivirals, and it offers an up-to-date treatment algorithm.

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
This paper presents the first report of an active therapeutic combination involving the CD30 chemoimmunoconjugate brentuximab vedotin in the primary management of early-stage Hodgkin lymphoma.

This week's complete table of contents

Why Submit to Blood?

Join the "This Week in Blood" mailing list by filling out the form below and clicking Subscribe!
*Email Address:
*First Name:
*Last Name:


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.